Sandoz Group AG (Sandoz Group AG) Debt-to-Equity : 0.53 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Debt-to-Equity?

Sandoz Group AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $323 Mil. Sandoz Group AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4,230 Mil. Sandoz Group AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $8,645 Mil. Sandoz Group AG's debt to equity for the quarter that ended in Dec. 2023 was 0.53.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sandoz Group AG's Debt-to-Equity or its related term are showing as below:

SDZNY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.28 Max: 0.53
Current: 0.53

During the past 2 years, the highest Debt-to-Equity Ratio of Sandoz Group AG was 0.53. The lowest was 0.04. And the median was 0.28.

SDZNY's Debt-to-Equity is ranked worse than
67.41% of 847 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs SDZNY: 0.53

Sandoz Group AG Debt-to-Equity Historical Data

The historical data trend for Sandoz Group AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Debt-to-Equity Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

Debt-to-Equity

0.04

0.53

Sandoz Group AG Quarterly Data
	Dec22	Dec23
Debt-to-Equity	0.04	0.53

Competitive Comparison of Sandoz Group AG's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Debt-to-Equity falls into.

Sandoz Group AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sandoz Group AG's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(323	+	4230)	/	8645
	=	0.53

Sandoz Group AG's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(323	+	4230)	/	8645
	=	0.53

Sandoz Group AG (OTCPK:SDZNY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sandoz Group AG Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024